Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros




Base de datos
Intervalo de año de publicación
1.
Tech Vasc Interv Radiol ; 26(2): 100900, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37865450

RESUMEN

Treating cancer patients with deep venous thrombosis/venous thromboembolism (DVT/VTE) can be challenging as patients are frequently unable to receive the standard therapy of anticoagulation due to the increased risk of bleeding complications seen in this population. Similarly, the hesitation of interventionalists to use thrombolytic agents due to bleeding risks limits percutaneous intervention options as well. Further, outcome data and guidelines do not exist for oncologic patients and often treatment is tailored to patient-specific factors after multidisciplinary discussion. This article reviews specific factors to consider when planning percutaneous treatment of cancer patients with DVT/VTE, focusing on the iliocaval system.


Asunto(s)
Neoplasias , Tromboembolia Venosa , Trombosis de la Vena , Humanos , Terapia Trombolítica/efectos adversos , Trombosis de la Vena/diagnóstico por imagen , Trombosis de la Vena/terapia , Tromboembolia Venosa/terapia , Anticoagulantes/efectos adversos , Trombectomía/efectos adversos , Catéteres/efectos adversos , Resultado del Tratamiento , Neoplasias/complicaciones , Neoplasias/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA